Here’s What the Street is Saying About Eli Lilly and Company (LLY)
Key takeaways
- Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281.
- The same day, Wolfe Research also maintained an Outperform rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,350.
- Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products.
Here’s What the Street is Saying About Eli Lilly and Company (LLY) Noor Ul Ain Rehman Tue, May 26, 2026 at 7:10 PM GMT+7 1 min read LLY TFC Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 clinical trial data in obesity announced the same day marks a new benchmark for anti-obesity medications, showing that patients on retatrutide high dose of 12 mg saw 28.3% weight loss at 80 weeks and 30.3% at 104 weeks. The firm told investors in a research note that it believes this will support retatrutide approval and use in patients that are not adequately served with existing incretin options.
The same day, Wolfe Research also maintained an Outperform rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,350. It told investors in a research note that the company’s reported pivotal phase 3 results for retatrutide further bolster its GLP-1 franchise leadership and differentiation in obesity therapeutics.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.